NCT06586580已完成不适用
Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate < 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy)
排除标准
- •Uveal melanoma
结局指标
主要结局
Objective response rate
时间窗: Month 18
次要结局
- Progression-free survival(Month 18)
- Overall survival(Month 18)
- Frequencies of severe toxicities leading to treatment interruption(Month 18)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.Breast NeoplasmsNCT06140576Zhejiang Cancer Hospital58
招募中
2 期
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecurrent Vulvar CancerPersistent Vulvar CancerMetastatic Vulva CancerLocally Advanced Vulvar CancerNCT05903833AGO Research GmbH42
进行中（未招募）
2 期
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaUterine CarcinosarcomaAdvanced Uterine CarcinosarcomaNCT05147558Memorial Sloan Kettering Cancer Center40
招募中
2 期
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerBiliary Tract Neoplasms ImmunotherapyNCT06230471Peking Union Medical College Hospital60
招募中
2 期
Merck IIT: RRP Pembro and LenvatinibHuman Papilloma VirusRecurrent Respiratory PapillomatosisNCT04645602Yale University20